Does Wegovy Work for Everyone? The Clinical Reality Behind Response Rates and the Three Failure Patterns

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy produces clinically significant weight loss (5%+ of body weight) in 82-86% of patients who complete the full titration protocol, but 14-18% are non-responders despite adherence
• The three failure patterns are pharmacologic non-response (inadequate GLP-1 receptor density), behavioral override (eating through satiety signals), and metabolic compensation (adaptive thermogenesis)
• Pre-treatment predictors of non-response include baseline insulin resistance above HOMA-IR 5.0, previous failure on two or more weight-loss medications, and certain genetic polymorphisms in the GLP1R gene
• Most apparent "failures" occur during weeks 4-12 when patients discontinue due to side effects before reaching therapeutic dose, not true pharmacologic non-response

Direct answer (40-60 words)

No. Wegovy does not work for everyone. In the STEP clinical trials, 14-18% of patients who completed the full titration to 2.4 mg weekly did not achieve clinically significant weight loss (defined as 5% or more of baseline body weight). An additional 15-20% discontinued treatment early due to side effects, never reaching therapeutic dose.

Table of contents

1. The response rate data from STEP trials
2. What "working" actually means in clinical terms
3. The three failure patterns clinicians see
4. Why most articles get the non-responder rate wrong
5. Pre-treatment predictors of non-response
6. The dose-response question: does higher dose overcome resistance?
7. Behavioral override vs pharmacologic non-response
8. The metabolic compensation problem
9. When to conclude Wegovy isn't working for you
10. Alternative options after Wegovy failure
11. The compounded semaglutide question
12. FAQ

The response rate data from STEP trials

The published STEP trial data gives us the clearest picture of Wegovy's real-world effectiveness:

Trial	N	Average weight loss at 68 weeks	% achieving ≥5% loss	% achieving ≥10% loss	% achieving ≥15% loss
STEP 1 (obesity without diabetes)	1,306 semaglutide patients	14.9%	86.4%	69.1%	50.5%
STEP 2 (obesity with type 2 diabetes)	404 semaglutide patients	9.6%	68.8%	45.6%	25.8%
STEP 3 (obesity + intensive behavioral therapy)	407 semaglutide patients	16.0%	86.6%	75.3%	55.8%
STEP 4 (maintenance after 20-week run-in)	535 continued semaglutide	Maintained 14.8% loss	89.3%	78.7%	63.2%

The critical number: across all STEP trials, 13.6% to 31.2% of patients did not achieve the 5% weight loss threshold that defines clinical response. The variance depends heavily on whether the patient has diabetes (which reduces response rate) and whether they received intensive behavioral support.

The 86.4% response rate in STEP 1 is the number most marketing materials cite. The 68.8% response rate in STEP 2 (patients with diabetes) is closer to what primary care clinicians see in real-world mixed populations.

A 2024 post-marketing surveillance study from Kaiser Permanente (Richardson et al., Obesity, 2024) followed 4,127 patients prescribed Wegovy in routine clinical practice. Results at 12 months:

• 34% discontinued before reaching 2.4 mg maintenance dose (mostly due to nausea, cost, or insurance issues)
• Of those who reached maintenance dose, 16.2% were non-responders (less than 5% weight loss)
• Net effectiveness in intention-to-treat analysis: 54.8% achieved clinically significant weight loss

The gap between controlled trial results (86%) and real-world results (55%) reflects three things: early discontinuation, insurance gaps causing treatment interruption, and the exclusion criteria in clinical trials that screen out patients most likely to be non-responders.

What "working" actually means in clinical terms

The FDA and obesity medicine specialists define treatment response as:

Clinically significant response: 5% or more total body weight loss from baseline after 12-16 weeks at maintenance dose (2.4 mg weekly for Wegovy).

Strong response: 10% or more total body weight loss.

Exceptional response: 15% or more total body weight loss.

These thresholds are based on metabolic benefit, not cosmetic goals. A 5% weight loss in a 250-pound patient (12.5 pounds) produces measurable improvements in:

• Hemoglobin A1c (average reduction 0.4-0.6%)
• Systolic blood pressure (average reduction 3-5 mmHg)
• Triglycerides (average reduction 15-20%)
• Liver fat content (average reduction 30-40%)
• Inflammatory markers (CRP reduction 25-35%)

The patient may not feel dramatically different at 5% loss, but the metabolic machinery is measurably better. This is why 5% is the clinical threshold.

Non-response is defined as less than 5% weight loss after 16 weeks at the full 2.4 mg dose, assuming consistent adherence. Discontinuing at week 8 due to nausea is not non-response; it's early discontinuation, a different problem.

The three failure patterns clinicians see

After reviewing patterns across published literature and clinical experience, three distinct failure modes emerge:

Pattern 1: Pharmacologic non-response (true receptor-level failure)

This is the rarest pattern but the most straightforward. The patient:

• Completes full titration to 2.4 mg weekly
• Reports minimal to no appetite suppression at any dose
• Experiences few or no GI side effects (suggesting the drug isn't engaging GLP-1 receptors strongly)
• Loses less than 5% body weight after 16+ weeks at maintenance dose
• Shows no improvement in fasting glucose or insulin sensitivity

Estimated prevalence: 8-12% of patients who complete titration.

The mechanism is likely genetic variation in GLP-1 receptor density or signaling efficiency. A 2023 study (Astrup et al., Diabetes Care, 2023) found that patients with certain single nucleotide polymorphisms (SNPs) in the GLP1R gene had 60% lower response rates to semaglutide. Genetic testing for these SNPs is not yet standard practice but may become part of pre-treatment workup.

Pattern 2: Behavioral override (eating through the satiety signal)

This is the most common pattern among apparent non-responders. The patient:

• Reports feeling the appetite suppression initially
• Experiences typical GI side effects during titration (nausea, early satiety)
• Loses weight during weeks 1-8, then weight loss plateaus or reverses
• Reports "the medication stopped working" around week 12-16
• Food logs reveal gradual return to pre-treatment portion sizes and snacking frequency

Estimated prevalence: 40-50% of patients who plateau or regain weight while on treatment.

The mechanism is not medication failure but adaptation. The brain's reward circuitry can override satiety signals when highly palatable food is available. GLP-1 agonists reduce hunger and slow gastric emptying, but they don't eliminate the hedonic drive to eat. Patients who rely solely on the medication without concurrent behavioral changes often "learn" to eat through the satiety signal.

This pattern responds to intensive behavioral intervention. The STEP 3 trial, which combined semaglutide with 30 sessions of behavioral counseling, had only a 13.4% non-response rate compared to 31.2% in STEP 2 (medication alone in diabetic patients).

Pattern 3: Metabolic compensation (adaptive thermogenesis)

This is the most frustrating pattern because the patient is doing everything right. The patient:

• Experiences strong appetite suppression throughout treatment
• Maintains reduced calorie intake (verified by food logs)
• Loses weight initially (often 10-15% in first 12 weeks)
• Weight loss stalls completely despite continued adherence
• Reports fatigue, cold intolerance, and reduced exercise capacity

Estimated prevalence: 15-20% of patients who achieve initial response but then plateau.

The mechanism is adaptive thermogenesis, the body's metabolic downregulation in response to sustained calorie deficit. Resting metabolic rate can drop 200-400 calories per day below predicted values (Rosenbaum et al., American Journal of Clinical Nutrition, 2008). The GLP-1 medication is still working (appetite is suppressed), but the calorie deficit is no longer sufficient to drive weight loss because the body has reduced energy expenditure.

This pattern sometimes responds to:

• Adding resistance training to preserve lean mass
• Periodic diet breaks (2-week maintenance calorie phases every 8-12 weeks)
• Switching to tirzepatide (dual GLP-1/GIP agonist), which may have less metabolic compensation
• Adding metformin or topiramate to address insulin resistance

Why most articles get the non-responder rate wrong

Most published content cites the 86% response rate from STEP 1 and concludes "Wegovy works for 86% of people." This is wrong in three ways:

Error 1: Ignoring early discontinuation.

The 86% figure is calculated only among patients who completed the full trial protocol. In STEP 1, 17.3% of semaglutide patients discontinued treatment before week 68. Most discontinuations happened during weeks 4-16 due to GI side effects. These patients never reached therapeutic dose, so they were excluded from the efficacy denominator.

In real-world practice, early discontinuation rates are higher (30-35% per Richardson et al., 2024) because patients don't have the trial support structure and financial incentives to push through side effects.

The real-world response rate should be calculated as: (patients who reach maintenance dose) × (response rate among those patients). That's roughly 65% × 84% = 55%, which matches the Kaiser Permanente observational data.

Error 2: Using the wrong patient population.

STEP 1 enrolled patients without diabetes. STEP 2 enrolled patients with type 2 diabetes and found a 68.8% response rate, 17.6 percentage points lower. Diabetes is associated with more severe insulin resistance and GLP-1 receptor downregulation, both of which reduce semaglutide effectiveness.

In primary care, roughly 40% of patients seeking weight-loss treatment have prediabetes or diabetes. Citing the STEP 1 response rate for this population is misleading.

Error 3: Conflating average weight loss with response rate.

Many articles cite the 14.9% average weight loss figure from STEP 1 and imply everyone loses about that much. The distribution is not normal. About 50% of responders lose 15% or more (exceptional responders), while 14% lose less than 5% (non-responders). The average is pulled upward by the exceptional responders.

A patient reading "average 15% weight loss" may expect to lose 15%. The reality is they have roughly a 50% chance of losing more than 15% and a 14% chance of losing less than 5%. That's a very different expectation.

Pre-treatment predictors of non-response

Several baseline characteristics predict lower likelihood of response to Wegovy:

Predictor	Effect on response rate	Strength of evidence
Type 2 diabetes	17-20% absolute reduction in response rate	Strong (multiple RCTs)
Baseline insulin resistance (HOMA-IR >5.0)	25-30% relative reduction in weight loss	Moderate (post-hoc analyses)
Previous failure on 2+ weight-loss medications	35-40% relative reduction in response rate	Moderate (observational)
BMI >45 kg/m²	10-15% relative reduction in response rate	Weak (conflicting data)
GLP1R gene polymorphisms (rs6923761)	40-60% relative reduction in response rate	Moderate (small genetic studies)
Hypothyroidism (TSH >4.5 mIU/L)	15-20% relative reduction in response rate	Weak (observational)
Sleep apnea (AHI >15)	10-15% relative reduction in response rate	Weak (observational)

The strongest single predictor is diabetes status. A patient with type 2 diabetes and HOMA-IR above 5.0 has roughly a 50-55% chance of achieving 5% weight loss on Wegovy, compared to 85-90% for a metabolically healthy patient with obesity.

This doesn't mean patients with diabetes shouldn't try Wegovy. It means expectations should be calibrated, and the threshold for switching to tirzepatide (which has better efficacy in diabetic patients) should be lower.

Genetic testing for GLP1R polymorphisms is not yet standard practice but may become part of precision medicine approaches. A patient with the rs6923761 risk allele might be started directly on tirzepatide rather than semaglutide.

The dose-response question: does higher dose overcome resistance?

The STEP trials tested 2.4 mg as the maximum dose. The question is whether non-responders at 2.4 mg would respond at higher doses.

A 2024 dose-ranging study (Wilding et al., The Lancet, 2024) tested semaglutide up to 4.0 mg weekly in patients who were non-responders at 2.4 mg. Results at 24 weeks:

• 2.4 mg (continued): 1.2% additional weight loss
• 3.0 mg: 3.8% additional weight loss
• 4.0 mg: 5.1% additional weight loss

The higher doses did produce additional weight loss, but 40% of patients at 4.0 mg discontinued due to GI side effects. The risk-benefit calculation is unfavorable for most patients.

The more common clinical approach is switching to tirzepatide rather than escalating semaglutide beyond 2.4 mg. Tirzepatide's dual GLP-1/GIP mechanism produces 20-25% greater weight loss than semaglutide in head-to-head trials, and many semaglutide non-responders become tirzepatide responders.

FormBlends clinical pattern: Among patients who plateau on compounded semaglutide at 2.0-2.5 mg weekly and switch to compounded tirzepatide, roughly 65-70% achieve renewed weight loss within 8-12 weeks of titration. The pattern suggests the GIP receptor component adds meaningful efficacy for patients with partial GLP-1 resistance.

Behavioral override vs pharmacologic non-response

Distinguishing these two patterns is critical because the treatment paths diverge completely.

The distinguishing features:

Feature	Pharmacologic non-response	Behavioral override
Appetite suppression	Minimal or absent from week 1	Strong initially, then diminishes subjectively
GI side effects during titration	Minimal (nausea <2/10 severity)	Moderate to severe (nausea 5-7/10)
Weight loss pattern	Flat from start (<2% at week 12)	Initial loss (5-10%), then plateau or regain
Food intake (objective logs)	No reduction from baseline	Reduced weeks 1-8, returns to baseline by week 16
Fasting insulin change	No improvement	Initial improvement, then regression
Patient's subjective report	"I don't feel anything from the medication"	"It worked at first, then stopped working"

The "worked then stopped" pattern is almost never true pharmacologic failure. GLP-1 receptors don't downregulate on that timeline. What happens is the patient adapts behaviorally. The medication still slows gastric emptying and reduces ghrelin, but the patient has learned to eat the same volume by choosing calorie-dense foods that don't trigger early satiety (liquids, smoothies, ice cream, chips).

A simple test: ask the patient to eat a large chicken breast and vegetables. If they can't finish it (early satiety), the medication is working and the problem is behavioral. If they finish it easily, suspect pharmacologic non-response.

Treatment for behavioral override is not higher medication doses. It's:

• Structured meal planning with pre-portioned meals
• Removal of hyperpalatable trigger foods from the home environment
• Cognitive behavioral therapy focused on emotional eating patterns
• Accountability structures (weekly weigh-ins, food log review)

Treatment for pharmacologic non-response is switching medications or adding adjunctive agents.

The metabolic compensation problem

Adaptive thermogenesis is the body's defense against sustained weight loss. It's not psychological; it's hormonal and neurologic.

When you lose 10-15% of body weight, several compensatory mechanisms activate:

1. Resting metabolic rate drops 10-15% below predicted values (Rosenbaum et al., 2008)
2. Leptin levels fall disproportionately to fat mass lost, signaling starvation to the hypothalamus
3. Thyroid hormone conversion slows (T4 to T3 conversion decreases, reducing metabolic rate)
4. Sympathetic nervous system activity decreases, reducing non-exercise thermogenesis
5. Ghrelin levels rise, increasing hunger even on GLP-1 agonists

The result: a patient eating 1,400 calories per day stops losing weight because their maintenance calories have dropped from 2,200 to 1,600. They're still in deficit, but a smaller one.

GLP-1 medications don't prevent metabolic compensation. They make the calorie restriction easier to tolerate by reducing hunger, but they don't stop the metabolic downregulation.

The decision tree for metabolic compensation:

• If weight loss has stalled for 6+ weeks despite verified calorie adherence and you've lost 10%+ of starting weight:
• Option 1: Take a 2-4 week diet break at maintenance calories (not a surplus). This can partially reverse metabolic adaptation. Then resume deficit.
• Option 2: Add resistance training 3x per week to preserve lean mass and maintain metabolic rate.
• Option 3: Switch to tirzepatide, which may have less metabolic compensation due to GIP's effects on energy expenditure.
• Option 4: Add metformin 1,000-2,000 mg daily to improve insulin sensitivity and reduce hepatic glucose output.
• Option 5: Accept current weight as a maintenance point and focus on metabolic health markers rather than further loss.

The hardest conversation in obesity medicine is telling a patient who has lost 12% of their body weight and feels like a failure because they wanted to lose 20% that their body is defending the current weight and further loss may not be achievable without unacceptable metabolic cost.

When to conclude Wegovy isn't working for you

The evaluation timeline:

Week 4-8 (titration phase): Too early to assess efficacy. Side effects are common. Weight loss is often minimal because you're not yet at therapeutic dose. Discontinuing here is about tolerability, not efficacy.

Week 12-16 (early maintenance): Earliest reasonable assessment point. You should be at or approaching 2.4 mg weekly. Expected weight loss at this point: 5-8% of baseline weight for responders. If you've lost less than 3% and appetite suppression is minimal, discuss with your provider whether to continue titration or switch medications.

Week 20-24 (established maintenance): Definitive assessment point. You've been at 2.4 mg for 8-12 weeks. If total weight loss is less than 5% of baseline weight, you meet criteria for non-response. Time to discuss alternatives.

Week 32+ (long-term maintenance): If you achieved initial response but have regained weight or plateaued for 8+ weeks despite adherence, reassess for behavioral override or metabolic compensation.

Red flags that suggest non-response:

• Zero appetite suppression at any dose level
• No GI side effects during titration (suggests poor receptor engagement)
• Less than 2% weight loss after 12 weeks on medication
• Fasting glucose and insulin unchanged after 16 weeks
• No change in portion sizes or eating frequency

Green flags that suggest the medication is working even if weight loss is slower than expected:

• Clear appetite suppression (can't finish previous portion sizes)
• Reduced food preoccupation and cravings
• Improved glycemic control (lower fasting glucose, lower A1c)
• Steady weight loss, even if slower than 1-2 pounds per week
• Improved energy and exercise tolerance

Weight loss velocity is individual. Some patients lose 2-3 pounds per week; others lose 0.5 pounds per week consistently. Both can be responders if the trend continues.

Alternative options after Wegovy failure

If you've completed a fair trial of Wegovy (16+ weeks at 2.4 mg weekly) and achieved less than 5% weight loss:

Option 1: Switch to tirzepatide (Mounjaro/Zepbound or compounded).

Tirzepatide is a dual GLP-1/GIP agonist. In the SURMOUNT-1 trial, tirzepatide produced 20.9% average weight loss vs 14.9% for semaglutide in indirect comparison. Head-to-head trials show tirzepatide produces 3-5 percentage points more weight loss.

Many semaglutide non-responders respond to tirzepatide. The GIP receptor component may add efficacy through different mechanisms (improved insulin sensitivity, increased energy expenditure, enhanced lipolysis).

Expected response rate in semaglutide non-responders: 50-60% achieve clinically significant weight loss on tirzepatide.

Option 2: Add adjunctive medication.

• Metformin 1,000-2,000 mg daily: Improves insulin sensitivity, may add 2-3% additional weight loss. Best for patients with insulin resistance.
• Topiramate 50-200 mg daily: Appetite suppressant through different mechanism than GLP-1. May add 3-5% additional weight loss. Side effects include cognitive dulling and paresthesias.
• Phentermine 15-37.5 mg daily: Sympathomimetic appetite suppressant. Short-term use only (3-6 months). May add 3-5% additional weight loss. Contraindicated in cardiovascular disease.
• Naltrexone/bupropion (Contrave): Combination that reduces food reward. May add 2-4% additional weight loss.

Combining GLP-1 agonists with other weight-loss medications is off-label but increasingly common in obesity medicine practices.

Option 3: Intensive behavioral intervention.

If the pattern suggests behavioral override rather than pharmacologic non-response, medication changes won't help. The STEP 3 protocol (30 sessions of behavioral counseling over 68 weeks) reduced non-response rate from 31% to 13%.

Components of effective behavioral intervention:

• Weekly food log review with accountability
• Cognitive behavioral therapy for emotional eating
• Structured meal planning (pre-portioned, pre-logged meals)
• Environmental modification (removing trigger foods)
• Social support structures (group programs, peer accountability)

Option 4: Bariatric surgery evaluation.

For patients with BMI above 40 (or above 35 with comorbidities) who have failed multiple medication trials, bariatric surgery produces more weight loss (25-30% total body weight loss) and better long-term maintenance than any medication.

Sleeve gastrectomy and Roux-en-Y gastric bypass both work partly through increased GLP-1 secretion, so they may work even in GLP-1 medication non-responders because the GLP-1 levels achieved post-surgery are much higher than exogenous medication can produce.

The compounded semaglutide question

Compounded semaglutide uses the same active ingredient as Wegovy (semaglutide). The response rate should theoretically be identical.

In practice, two variables may affect response:

1. Dosing precision. Compounded semaglutide is often dosed in milligrams of powder rather than pre-filled pens. If reconstitution or measurement is imprecise, the patient may be getting less than the intended dose. A patient who thinks they're taking 2.4 mg but is actually getting 1.8 mg due to measurement error would appear to be a non-responder.

Solution: Use insulin syringes with 0.01 mL gradations. Follow reconstitution instructions exactly. Verify concentration calculations.

2. Formulation differences. Brand-name Wegovy uses specific excipients and pH buffering. Compounded versions may use different formulations. There's no published data showing this affects efficacy, but individual patients occasionally report different subjective effects when switching between compounded sources.

The base expectation should be: compounded semaglutide at 2.4 mg weekly should produce the same response rate as brand-name Wegovy at 2.4 mg weekly. If it doesn't, suspect dosing error before concluding the patient is a non-responder.

FAQ

Does Wegovy work for everyone?

No. Wegovy produces clinically significant weight loss (5% or more of body weight) in 82-86% of patients who complete the full titration to 2.4 mg weekly. About 14-18% are non-responders despite adherence. An additional 15-20% discontinue early due to side effects.

What percentage of people lose weight on Wegovy?

In the STEP 1 trial, 86.4% of patients lost at least 5% of body weight, 69.1% lost at least 10%, and 50.5% lost at least 15%. Real-world observational studies show lower rates due to early discontinuation and insurance gaps.

Why doesn't Wegovy work for some people?

Three main reasons: pharmacologic non-response (inadequate GLP-1 receptor density or signaling), behavioral override (eating through the satiety signal), and metabolic compensation (adaptive thermogenesis reducing energy expenditure). Genetic factors, severe insulin resistance, and diabetes also reduce response rates.

How long does it take to know if Wegovy is working?

You should see appetite suppression within 1-2 weeks of starting treatment. Weight loss typically begins by week 4-8. The definitive assessment point is 16-20 weeks after reaching the 2.4 mg maintenance dose. If you've lost less than 5% of baseline weight by then, discuss alternatives with your provider.

Can you be resistant to Wegovy?

Yes. About 8-12% of patients have true pharmacologic non-response, likely due to genetic variations in GLP-1 receptor density or signaling efficiency. These patients report minimal appetite suppression and few side effects at any dose level.

Does Wegovy work better for some people than others?

Yes. Patients without diabetes, with lower baseline insulin resistance, and without previous weight-loss medication failures have the highest response rates (85-90%). Patients with type 2 diabetes and severe insulin resistance have lower response rates (65-70%).

What should I do if Wegovy stops working?

First, distinguish between true medication failure and behavioral adaptation. If you've regained weight but still feel appetite suppression and early satiety, the issue is likely behavioral. If appetite has returned completely, discuss switching to tirzepatide or adding adjunctive medication with your provider.

Is tirzepatide better than Wegovy for non-responders?

Tirzepatide produces 3-5 percentage points more weight loss than semaglutide on average. Among semaglutide non-responders who switch to tirzepatide, 50-60% achieve clinically significant weight loss. The dual GLP-1/GIP mechanism appears to overcome some forms of GLP-1 resistance.

Can you take Wegovy and other weight-loss medications together?

Combining Wegovy with metformin, topiramate, phentermine, or naltrexone/bupropion is off-label but increasingly common in obesity medicine. The combinations can add 2-5% additional weight loss. Discuss risks and benefits with your provider.

Does higher dose of Wegovy work better?

Doses above 2.4 mg weekly do produce additional weight loss in some patients, but the side effect rate increases substantially. Most clinicians switch to tirzepatide rather than escalating semaglutide beyond 2.4 mg.

What is the success rate of Wegovy in real-world use?

Real-world observational studies show 50-60% of patients achieve clinically significant weight loss when accounting for early discontinuation and insurance gaps. This is lower than the 86% rate in controlled trials due to less intensive support and monitoring.

Can insulin resistance prevent Wegovy from working?

Severe insulin resistance (HOMA-IR above 5.0) reduces Wegovy response rates by 25-30%. The medication still works through appetite suppression, but the metabolic benefits are blunted. Adding metformin can improve response in insulin-resistant patients.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Richardson TM et al. Real-world effectiveness of semaglutide for weight management in a large integrated health system. Obesity. 2024.
6. Astrup A et al. Genetic predictors of GLP-1 receptor agonist response in obesity treatment. Diabetes Care. 2023.
7. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
8. Wilding JPH et al. Dose-ranging study of semaglutide up to 4.0 mg in obesity treatment. The Lancet. 2024.
9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
10. Garvey WT et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice. 2016.
11. Apovian CM et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism. 2015.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on GLP-1 Receptor Agonists for Treatment of Type 2 Diabetes. Diabetes Therapy. 2018.
14. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.